查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1931245

植入式药物洗脱支架市场（按支架代数、聚合物涂层、药物涂层和最终用户划分），全球预测，2026-2032年

Implantable Drug Eluting Stent Market by Stent Generation, Polymer Coating, Drug Coating, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年植入式药物释放型支架市值为37.7亿美元，预计到2026年将达到40.5亿美元，年复合成长率为8.53%，到2032年将达到66.9亿美元。

关键市场统计数据
基准年 2025 37.7亿美元
预计年份：2026年 40.5亿美元
预测年份 2032 66.9亿美元
复合年增长率 (%) 8.53%

建构临床、商业性和监管环境框架，以塑造植入式药物释放型支架生态系统中的创新应用和策略重点。

植入式药物释放型支架市场处于医疗创新、监管审查和医疗服务模式变革的交汇点。本报告首先界定了医疗设备製造商、医院系统和专业经销商所处的临床和商业性环境。报告揭示了治疗重点——改善血管癒合、减少血管再阻塞和最大限度地降低晚期血栓事件——如何推动器械设计和药物涂层的持续改进，并说明了报销压力和采购惯例如何影响临床实践中的应用曲线。

检验融合的技术、临床和分销变革，这些变革将重新定义竞争优势并推动下一代药物释放型支架的普及应用。

过去五年发生了翻天覆地的变化，重塑了植入式药物释放型支架的竞争优势，并影响采购决策。聚合物技术的进步加速了从耐用涂层向生物可吸收、无聚合物设计的转变，改变了介入性心臟病专家的风险获益评估，并促使开展了以长期血管癒合为重点的新临床试验。同时，药物涂层的发展也超越了传统药物；虽然Everolimus和Sirolimus仍然是基础药物，但药物释放曲线的选择性优化和新型辅料的引入，创造了差异化的性能属性，并促成了直接对比试验的开展。

评估2025年关税调整和贸易政策转变如何重塑支架製造商和供应商的采购、成本结构和供应链韧性。

美国2025年实施的关税和贸易政策调整，为植入式药物释放型支架全球供应链的营运企业带来了更多复杂性。某些医疗设备组件和上游原料关税的提高，增加了从国际供应商采购聚合物树脂、特殊金属和某些活性药物成分的製造商的投入成本。为此，医疗设备製造商正在重新审视其筹资策略，加快对替代供应商的资格认证，并调整库存政策，以确保供应的连续性，同时控制利润压力。

深入的細項分析，将终端用户需求、设备世代、聚合物策略、药物包衣和分销管道与商业性和临床优先事项相匹配。

细分市场分析揭示了临床、营运和商业性动态的交汇点，这些因素会影响产品定位和通路策略。按最终用户划分，市场细分为门诊手术中心、心臟导管介入检查室和医院。心臟导管介入检查室进一步细分为检查室实验室和公共检查室。医院进一步细分为私立医院和公立医院。这些最终用户的区别至关重要：门诊机构优先考虑的是吞吐量、简化的库存管理和设备的易用性，而医院系统则重视广泛的临床适应性、长期疗效数据以及能够兼顾住院和门诊病人收入的整合采购流程。

区域趋势和医疗保健系统差异将影响全球市场的证据要求、分发策略和采纳路径

区域趋势对生物可吸收药物释放型支架的监管时间表、临床实践模式和分销模式有显着影响。在美洲地区，激烈的医保报销谈判、三级医疗中心的高手术量以及择期手术日益转移到门诊的趋势，正在塑造该地区的商业环境。这些因素促使市场对能够提供可预测的临床结果、简化的库存管理以及强有力的上市后证据以支持合约决策的医疗器材的需求不断增长。

竞争行动和企业策略优先考虑临床差异化、生产弹性和证据生成，以确保长期市场地位。

植入式药物释放型支架领域的企业竞争格局反映了技术能力、临床证据、生产规模和通路执行力之间的平衡。成熟的跨国公司往往凭藉其广泛的临床试验项目、整合的销售团队和全球製造地，在关键地区保持领先地位。同时，新兴企业则专注于材料科学创新、特定患者群体或成本效益高的生产方式，试图占据特定细分市场。

为製造商和相关人员提供切实可行的策略措施，以加强其证据策略、保障供应链安全并优化混合上市策略。

为了驾驭不断变化的药物释放型支架市场，产业领导者应协调产品开发、临床证据产生和商业化，以降低市场进入门槛并提升长期价值。应优先考虑将材料和药物创新与切实可行的临床试验设计相结合的开发路径，从而产生符合监管要求的结果以及适用于与支付方讨​​论的真实世界证据。这种双重证据方法将透过展示疗效和实用性来加速医院系统的审批流程，并有助于合约谈判。

采用严谨的混合方法研究策略，结合与临床相关人员的直接沟通、二手文献综合分析和分析建模，以得出可操作且有效的研究结果。

本研究采用混合方法，结合与主要相关人员的直接对话、二手资料综合和分析建模，以确保获得全面且可靠的见解。主要研究包括对介入性心臟病专家、医院和门诊中心的采购人员、监管事务专业人员以及分销合作伙伴进行结构化访谈，以了解他们对临床优先事项、采购行为和物流限制的细緻观点。这些访谈旨在探讨聚合物策略、药物包覆和器材迭代在实际决策中的相对重要性。

将创新转化为持续的临床应用和强大的商业性优势的关键趋势和策略原则的综合分析

总之，植入式药物释放型支架市场正随着材料科学、药物传递技术和商业化模式的同步创新而不断发展。临床需求日益集中在那些不仅手术操作简便，而且能够促进血管长期癒合并最大限度降低併发症风险的器械。同时，分销通路的复杂性和近期的贸易趋势要求製造商在提高全球采购效率、实现在地化生产和建立稳健的物流系统之间取得平衡。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依支架代别植入式药物洗脱支架市场

  • 第一代
  • 第二代
  • 第三代

第九章 依聚合物涂层分類的植入式药物洗脱支架市场

  • 生物可吸收聚合物
    • 聚左旋乳酸
    • 聚乙醇酸
  • 耐用聚合物
  • 不含聚合物

第十章 依药物涂层分類的植入式药物洗脱支架市场

  • Everolimus
  • 紫杉醇
  • Sirolimus
  • 佐他罗莫司

第十一章植入式药物洗脱支架市场（依最终用户划分）

  • 门诊手术中心
  • 心臟导管检查室
  • 医院
    • 私立医院
    • 公立医院

第十二章植入式药物洗脱支架市场（依地区分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章植入式药物洗脱支架市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国植入式药物洗脱支架市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国植入式药物洗脱支架市场

第十六章：中国植入式药物洗脱支架市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Alvimedica Medical Technologies Inc.
  • B. Braun Melsungen AG
  • Balton Sp. z oo
  • Biosensors International Group, Ltd.
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Concept Medical, Inc.
  • Cook Medical Incorporated
  • Elixir Medical Corporation
  • Eucatech AG
  • Eurocor GmbH
  • iVascular SLU
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Medinol Ltd.
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • OrbusNeich Medical Group
  • Sahajanand Medical Technologies Ltd.
  • Terumo Corporation
Product Code: MRR-7B550E008DE1

The Implantable Drug Eluting Stent Market was valued at USD 3.77 billion in 2025 and is projected to grow to USD 4.05 billion in 2026, with a CAGR of 8.53%, reaching USD 6.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.77 billion
Estimated Year [2026] USD 4.05 billion
Forecast Year [2032] USD 6.69 billion
CAGR (%) 8.53%

Framing the clinical, commercial, and regulatory context that shapes innovation adoption and strategic priorities across the implantable drug eluting stent ecosystem

The implantable drug eluting stent market sits at the intersection of medical innovation, regulatory scrutiny, and shifting care delivery models. This report begins by framing the clinical and commercial context in which device manufacturers, hospital systems, and specialty distributors operate. It clarifies how therapeutic priorities-improving vascular healing, reducing restenosis, and minimizing late thrombotic events-drive continuous iteration in device design and pharmacologic coatings, while reimbursement pressures and procurement practices influence adoption curves across care settings.

From a clinical perspective, physicians increasingly favor technologies that balance deliverability, acute performance, and long-term vessel integrity. Emerging polymer strategies and novel antiproliferative agents aim to shorten recovery windows and mitigate adverse events, prompting hospitals and catheterization laboratories to reassess procurement criteria. Concurrently, payers and health systems place more emphasis on health-economic outcomes and real-world evidence to justify premium pricing and to support pathway integration.

Commercially, competitive dynamics are shaped by a small number of established multinational firms and a growing cohort of specialized entrants focused on polymer science and drug chemistry. This landscape fosters both consolidation and targeted partnership strategies between device makers and contract manufacturers. Taken together, the introduction sets expectations for a market where clinical efficacy, regulatory compliance, supply chain resilience, and channel sophistication jointly determine which innovations achieve durable clinical and commercial success.

Examining the converging technological, clinical, and distribution shifts that redefine competitive advantage and drive adoption of next-generation drug eluting stents

The past five years have seen transformative shifts that reconfigure competitive advantage and influence procurement decisions for implantable drug eluting stents. Advances in polymer technology have accelerated the transition from durable coatings to bioabsorbable and polymer-free designs, altering the risk-benefit calculus for interventional cardiologists and prompting new clinical trials focused on long-term vessel healing. Simultaneously, drug coating evolution has expanded beyond traditional agents; while Everolimus and Sirolimus remain foundational, selective optimization of drug-release profiles and novel excipients are creating differentiated performance characteristics that invite head-to-head comparative studies.

Care delivery transformation is another critical axis of change. Cardiac procedures are increasingly decentralized, with ambulatory surgery centers and private catheterization laboratories performing a growing share of elective interventions. This trend reshapes service expectations, procurement timelines, and stock management practices, while driving demand for stents that balance ease of handling with broad compatibility across imaging and interventional systems. Regulatory environments have also matured, placing greater emphasis on post-market surveillance and real-world evidence, which in turn incentivizes manufacturers to invest in longitudinal registries and digital follow-up solutions.

Finally, strategic partnerships and commercialization models have diversified. Manufacturers are experimenting with hybrid distribution, combining direct sales with specialized distributor arrangements and OEM partnerships to reach niche customer segments efficiently. The net effect of these transformative shifts is a market that rewards integrated clinical data, nimble supply chains, and product architectures designed for both immediate procedural performance and favorable long-term outcomes.

Assessing how 2025 tariff adjustments and trade policy shifts have reshaped sourcing, cost structures, and supply chain resilience for stent manufacturers and providers

Recent tariff actions and trade policy adjustments in the United States during 2025 introduced additional complexity for companies operating global supply chains for implantable drug eluting stents. Tariff increases on selected medical device components and upstream materials elevated input costs for manufacturers that source polymer resins, specialty metals, and certain active pharmaceutical ingredients from international suppliers. In response, device makers have revisited sourcing strategies, accelerated qualification of alternative suppliers, and adjusted inventory policies to preserve continuity of supply while managing margin pressure.

Beyond direct cost implications, the tariffs have had broader operational ripple effects. Companies with vertically integrated manufacturing that previously optimized global cost arbitrage faced renewed incentives to localize certain production stages to mitigate customs-related delays and duties. Contract manufacturers serving multiple OEMs experienced mixed impacts depending on their footprint and pass-through pricing power, prompting re-negotiations of long-term service agreements and lead-time commitments.

Clinicians and hospital procurement teams observed these shifts through changes in product availability, list prices, and contract terms. Some health systems prioritized multi-supplier strategies and framework agreements to insulate clinical programs from single-vendor disruptions. Moving forward, the cumulative impact of tariff changes underscores the need for scenario-based planning that incorporates customs risk, supplier redundancy, and cost-to-serve analysis when assessing new product introductions or portfolio expansions.

Detailed segmentation insights that align end-user needs, device generations, polymer strategies, drug coatings, and distribution channels to commercial and clinical priorities

Segmentation analysis reveals where clinical, operational, and commercial dynamics intersect to influence product positioning and channel strategy. Based on End User, market is studied across Ambulatory Surgery Centers, Cardiac Catheterization Laboratories, and Hospitals. The Cardiac Catheterization Laboratories is further studied across Private Laboratories and Public Laboratories. The Hospitals is further studied across Private Hospitals and Public Hospitals. These end-user distinctions are consequential: ambulatory settings prioritize throughput, simplified inventory, and device ease-of-use, while hospital systems emphasize broad clinical versatility, long-term outcomes data, and integrated purchasing processes that reflect inpatient and outpatient revenue considerations.

Product lifecycle and clinical differentiation also hinge on Stent Generation, market is studied across First Generation, Second Generation, and Third Generation. First generation devices established foundational antiproliferative approaches but faced limitations tied to durable polymer biocompatibility. Second generation iterations improved deliverability and drug kinetics, while third generation platforms emphasize bioabsorbable elements, thinner strut designs, and refined drug-release profiles, targeting improved vascular healing and lower long-term complication rates. These evolutionary steps create distinct value propositions that influence clinician preference and formulary inclusion.

Material science and polymer strategy carry further implications for regulatory pathways and clinician acceptance. Based on Polymer Coating, market is studied across Bioabsorbable Polymer, Durable Polymer, and Polymer Free. The Bioabsorbable Polymer is further studied across Poly-L-Lactic Acid and Polyglycolic Acid. Devices built on bioabsorbable polymers may reduce chronic inflammation and late adverse events, but they require robust long-term evidence and meticulous manufacturing controls. Durable polymer platforms remain attractive for proven performance and predictable drug release, whereas polymer-free designs aim to minimize foreign-body exposure, offering differentiated risk profiles that can appeal to specific patient cohorts.

Pharmacologic selection also materially affects clinical use and competitive messaging. Based on Drug Coating, market is studied across Everolimus, Paclitaxel, Sirolimus, and Zotarolimus. Each agent brings unique pharmacodynamics and clinical legacy, influencing physician preference and trial design. Finally, distribution strategy shapes market access pathways. Based on Distribution Channel, market is studied across Direct Sales and Distributors. The Direct Sales is further studied across In-House and Oem Partnerships. The Distributors is further studied across Medical Device Wholesalers and Specialty Distributors. Direct sales models enable tighter clinical engagement and integrated training programs, while distributor networks provide reach, logistical support, and localized regulatory know-how. Taken together, these segmentation lenses provide a structured way to align product development, evidence generation, and go-to-market models with end-user priorities and clinical expectations.

Regional dynamics and healthcare system variations that determine evidence requirements, distribution strategies, and adoption pathways across global markets

Regional dynamics exert a powerful influence on regulatory timelines, clinical practice patterns, and distribution models for implantable drug eluting stents. In the Americas, commercial environments are shaped by competitive reimbursement negotiations, high procedural volumes in tertiary centers, and a growing trend of moving elective interventions toward ambulatory settings. These forces create a demand for devices that offer predictable clinical outcomes, streamlined inventory management, and strong post-market evidence to justify contracting decisions.

In Europe, Middle East & Africa, heterogeneity defines strategy. Regulatory harmonization efforts coexist with widely varying payer structures and hospital capabilities, from large academic centers in metropolitan hubs to smaller public hospitals and private clinics. Local procurement authorities often require region-specific clinical data or value dossiers, pushing manufacturers to design flexible evidence generation programs. Supply chain complexity in the region also makes distributor partnerships valuable for navigating customs, logistics, and service requirements.

Asia-Pacific combines rapid adoption of minimally invasive technologies with diverse regulatory pathways and manufacturing capabilities. High-volume centers in certain markets accelerate uptake of new stent generations, while cost-sensitive systems in other countries prioritize durable performance and procurement efficiency. Across all regions, demographic trends such as aging populations and rising cardiovascular disease prevalence sustain clinical demand, but regional variations in procedure settings and payer expectations necessitate bespoke commercialization strategies that reconcile global product standards with localized clinical and economic requirements.

Competitive behaviours and corporate strategies that prioritize clinical differentiation, manufacturing agility, and evidence generation to secure long-term positioning

Competitive positioning among companies in the implantable drug eluting stent arena reflects a balance of technological capabilities, clinical evidence, manufacturing scale, and channel execution. Established multinational firms frequently leverage broad clinical trial programs, integrated sales forces, and global manufacturing footprints to maintain leadership in core geographies, while specialized challengers concentrate on material science innovations, niche patient cohorts, or cost-efficient manufacturing to capture targeted segments.

Strategic behaviors observed across leading companies include investment in longitudinal registries, cross-functional collaborations with interventional cardiology opinion leaders, and selective vertical integration to manage key material inputs. Some firms prioritize strengthening OEM partnerships and contract manufacturing relationships to enhance production flexibility, whereas others focus on direct sales channels to preserve clinical engagement and margins. Portfolio rationalization is also evident: products with differentiated clinical profiles and compelling operational advantages receive prioritized development budgets, while legacy platforms are managed through life-cycle support and selective geographic withdrawals.

Mergers and acquisitions remain a tactical avenue to access manufacturing technologies, complementary product lines, or regulatory filings. Companies also increasingly adopt modular commercialization approaches that combine in-house clinical affairs teams with external data-services partners to accelerate real-world evidence generation. Collectively, these corporate strategies reveal a market that rewards clarity of clinical differentiation, supply-chain robustness, and the ability to translate technical innovation into demonstrable patient and system-level outcomes.

Actionable strategic moves for manufacturers and stakeholders to strengthen evidence strategies, secure supply chains, and optimize hybrid go-to-market approaches

To navigate the evolving implantable drug eluting stent landscape, industry leaders should align product development, clinical evidence generation, and commercialization to reduce adoption friction and enhance long-term value. Prioritize development pathways that couple material and drug innovations with pragmatic clinical trial designs that produce both regulatory-grade outcomes and real-world evidence suitable for payer engagement. This dual evidence approach accelerates credentialing with hospital systems and supports contracting discussions by demonstrating both efficacy and practical utility.

Supply-chain resilience is equally critical. Implement supplier diversification plans and qualify alternative material sources for polymer resins, specialty metals, and active pharmaceutical components to mitigate customs and tariff exposure. Consider nearshoring or regional manufacturing nodes to shorten lead times and reduce exposure to cross-border tariffs and logistical disruptions. Operationally, invest in demand-sensing capabilities that align production with procedural seasonality and evolving care-site mixes.

Commercial models should blend direct engagement where clinical complexity demands hands-on training with distributor relationships that enable reach into fragmented markets and resource-constrained institutions. Finally, foster clinician partnerships early to drive adoption pathways: co-develop training curricula, support longitudinal outcomes tracking, and facilitate peer-to-peer dissemination of best practices. Such integrated strategies position organizations to translate technical advances into sustained clinical uptake and commercial performance.

A rigorous mixed-methods research approach combining primary clinical engagement, secondary literature synthesis, and analytical modeling to produce actionable and defensible insights

This research applies a mixed-methods approach that blends primary stakeholder engagement with secondary data synthesis and analytical modeling to ensure comprehensive and defensible insights. Primary research included structured interviews with interventional cardiologists, procurement leaders across hospitals and ambulatory centers, regulatory affairs specialists, and distribution partners to capture nuanced perspectives on clinical priorities, purchasing behavior, and logistical constraints. These conversations were designed to probe the relative importance of polymer strategies, drug coatings, and device generations in real-world decision-making.

Secondary data inputs consisted of peer-reviewed clinical literature, regulatory filings, public clinical registry outputs, and company disclosures to contextualize primary findings and validate technical assertions. Data validation processes included triangulation across sources, cross-verification with clinical experts, and assessment of evidence quality to ensure recommendations rest on robust signals rather than isolated datapoints. The methodology places particular emphasis on longitudinal outcomes evidence and post-market performance metrics as key indicators of sustainable device value.

Analytical techniques incorporated segmentation mapping, scenario analysis for supply-chain exposures, and vendor capability assessments to translate qualitative insights into operationally relevant conclusions. Ethical safeguards and confidentiality protocols were observed during primary research to protect respondent anonymity and to promote candid participation. The methodology is therefore designed to support strategic decision-making by combining practitioner insight, technical literature, and pragmatic operational analysis.

Synthesis of key trends and strategic principles that convert technical innovation into durable clinical adoption and resilient commercial advantage

In conclusion, the implantable drug eluting stent market is advancing through parallel innovations in materials science, pharmacologic delivery, and commercialization models. Clinical demand increasingly favors devices that demonstrate not only procedural excellence but also favorable long-term vessel healing and minimized complication risk. At the same time, distribution complexities and recent trade dynamics require manufacturers to carefully balance global sourcing efficiencies with localized production and resilient logistics.

Strategic success will hinge on an integrated approach that connects technical differentiation with pragmatic evidence generation, supply-chain robustness, and hybrid go-to-market strategies tailored to end-user needs. Manufacturers that invest in diversified polymer platforms, targeted drug-release technologies, and comprehensive real-world outcomes programs will be better positioned to secure formulary acceptance and clinician preference across hospitals, private and public catheterization laboratories, and ambulatory surgery centers. Regional nuances across the Americas, Europe, Middle East & Africa, and Asia-Pacific underscore the importance of bespoke commercialization plans that reconcile global product standards with local regulatory and payer environments.

Ultimately, the most successful organizations will be those that convert innovation into demonstrable clinical and operational benefits while sustaining agility in sourcing and distribution. This balanced focus will enable them to respond to shifting care settings and policy environments while preserving the confidence of clinicians, payers, and patients alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Implantable Drug Eluting Stent Market, by Stent Generation

  • 8.1. First Generation
  • 8.2. Second Generation
  • 8.3. Third Generation

9. Implantable Drug Eluting Stent Market, by Polymer Coating

  • 9.1. Bioabsorbable Polymer
    • 9.1.1. Poly-L-Lactic Acid
    • 9.1.2. Polyglycolic Acid
  • 9.2. Durable Polymer
  • 9.3. Polymer Free

10. Implantable Drug Eluting Stent Market, by Drug Coating

  • 10.1. Everolimus
  • 10.2. Paclitaxel
  • 10.3. Sirolimus
  • 10.4. Zotarolimus

11. Implantable Drug Eluting Stent Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Cardiac Catheterization Laboratories
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals

12. Implantable Drug Eluting Stent Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Implantable Drug Eluting Stent Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Implantable Drug Eluting Stent Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Implantable Drug Eluting Stent Market

16. China Implantable Drug Eluting Stent Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Alvimedica Medical Technologies Inc.
  • 17.7. B. Braun Melsungen AG
  • 17.8. Balton Sp. z o.o.
  • 17.9. Biosensors International Group, Ltd.
  • 17.10. BIOTRONIK SE & Co. KG
  • 17.11. Boston Scientific Corporation
  • 17.12. Concept Medical, Inc.
  • 17.13. Cook Medical Incorporated
  • 17.14. Elixir Medical Corporation
  • 17.15. Eucatech AG
  • 17.16. Eurocor GmbH
  • 17.17. iVascular S.L.U.
  • 17.18. Lepu Medical Technology (Beijing) Co., Ltd.
  • 17.19. Medinol Ltd.
  • 17.20. Medtronic plc
  • 17.21. Meril Life Sciences Pvt. Ltd.
  • 17.22. OrbusNeich Medical Group
  • 17.23. Sahajanand Medical Technologies Ltd.
  • 17.24. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLY-L-LACTIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLY-L-LACTIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLY-L-LACTIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYGLYCOLIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYGLYCOLIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYGLYCOLIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY ZOTAROLIMUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY ZOTAROLIMUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY ZOTAROLIMUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY CARDIAC CATHETERIZATION LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY CARDIAC CATHETERIZATION LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY CARDIAC CATHETERIZATION LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 124. GCC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GCC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 126. GCC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 127. GCC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 128. GCC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 129. GCC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GCC IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 145. G7 IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. G7 IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 147. G7 IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 148. G7 IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 149. G7 IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 150. G7 IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. G7 IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. NATO IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. NATO IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 154. NATO IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 155. NATO IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 156. NATO IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 157. NATO IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NATO IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY STENT GENERATION, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATING, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY DRUG COATING, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA IMPLANTABLE DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)